Fulgent Genetics (FLGT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
No filing fee required for this submission.
Voting matters and shareholder proposals
Materials relate to matters requiring shareholder vote at the next meeting.
Shareholder rights and capital structure
Filing confirms compliance with SEC proxy rules and shareholder communication requirements.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fulgent Genetics
- 2026 revenue is forecast at $350M, with growth driven by acquisitions and AI-enabled expansion.FLGT
Q4 20257 Apr 2026 - Director elections, auditor ratification, and executive pay are up for shareholder vote in May 2026.FLGTProxy filing31 Mar 2026
- Proxy seeks approval for director elections, auditor, executive pay, and a new equity plan.FLGTProxy filing31 Mar 2026
- Growth in diagnostics and pharma, new VA contract, and margin gains highlight strong momentum.FLGTUBS Global Healthcare Conference 20243 Feb 2026
- Q2 revenue up 5% year-over-year, with margin gains and strong cash, but regulatory risks remain.FLGTQ2 20242 Feb 2026
- Q3 revenue $71.7M, core up 9% YoY, $99M VA contract, $10.1M impairment, strong cash.FLGTQ3 202415 Jan 2026
- 2024 growth is driven by lab services, new NIPT, and industry consolidation, with strong margins.FLGTPiper Sandler 36th Annual Healthcare Conference11 Jan 2026
- Strong organic growth, innovation, and clinical milestones drive future expansion.FLGTPiper Sandler 37th Annual Healthcare Conference3 Dec 2025
- Director elections, auditor ratification, and executive pay approval headline the 2025 meeting.FLGTProxy Filing1 Dec 2025